Dasatinib (Sprycel, Phyrago)

Dasatinib at a glance

Dasatinib is a tyrosine kinase inhibitor, or TKI. It blocks certain abnormal growth signals, including the BCR::ABL1 protein. Sprycel and Phyrago are verified brand names in the reviewed sources. A generic name alone does not tell you every formulation-specific instruction: acid-reducing medicines are a particularly important example.

Reviewed tablets come in 20, 50, 70, 80, 100 and 140 mg strengths. European Sprycel information also describes a powder prepared into a 10 mg/mL oral suspension. The tablets and suspension are not interchangeable milligram for milligram. Any switch requires a new, checked prescription. Tell the pharmacist about inherited sugar-processing disorders: Sprycel tablets contain lactose, and the European suspension contains sucrose, which also matters for diabetes.

Low blood counts, fluid retention, bowel symptoms, rash, headache and tiredness can occur. Serious infection, bleeding, heart or lung problems and liver injury also need attention. The pattern varies with the underlying condition, dose and other treatments; another person's experience cannot predict yours.

What dasatinib is and how it works

Some blood cancer cells produce an abnormal protein called BCR::ABL1 when parts of two genes join together. This can act like a growth signal that remains switched on. The associated chromosome change is often called the Philadelphia chromosome. Dasatinib inhibits BCR::ABL1 and other kinases, including SRC-family proteins, helping interrupt signals that allow affected cells to grow.

This is a small-molecule targeted medicine. It is not a checkpoint immunotherapy. Although treatment is selected for a particular biological feature, it can also affect healthy cells and cause substantial side effects. Blood-count changes and other toxicities do not mean that the medicine has targeted only the cancer.

The team assesses benefit using blood tests and disease-specific investigations. Feeling well is valuable but does not replace these measurements. Equally, needing a temporary pause or dose reduction for safety does not automatically mean treatment has failed.

How the team decides whether it is suitable

The team considers the precise diagnosis, chromosome or molecular results, disease phase, earlier medicines and your general health. Ask what the BCR::ABL1 or Philadelphia-chromosome result means in your situation. These changes in cancer cells are not automatically inherited changes that you have passed to your children.

Tell the team about previous fluid around the lungs, pulmonary hypertension, heart failure, irregular heartbeat, liver disease, hepatitis B, bleeding problems and every medicine you use. Previous reactions to a TKI may affect the choice and monitoring plan. Older people and those with heart or lung conditions may need particularly careful assessment.

Children need specialist prescribing based on their weight, formulation and complete treatment plan. Adult tablet doses must not be applied to a child. Growth and bone development need monitoring during paediatric treatment. If swallowing is difficult, discuss the problem before treatment starts rather than changing tablets yourself.

Before treatment starts

Blood tests usually include a full blood count, liver and kidney function, and blood salts such as potassium and magnesium. Low potassium or magnesium should be corrected because they can increase the risk of abnormal heart rhythms. A pregnancy test may be needed when pregnancy is possible.

European information requires hepatitis B testing before treatment. Previous infection can reactivate even if you have felt well for years. If testing is positive, the team should involve a clinician experienced in hepatitis B and arrange a prevention or monitoring plan. Do not assume that a past infection no longer matters.

A baseline heart and lung assessment helps identify existing problems. An ECG records the heart's electrical activity; an echocardiogram uses ultrasound to assess its structure and pumping. Which tests you need depends on symptoms, history, interacting medicines and clinical risk, rather than one fixed package for everyone.

Bring a complete medicine list, including acidity treatment, painkillers, blood thinners, vitamins and herbal products. Ask for written instructions about missed doses, symptoms requiring a call and whom to contact at night. If tumour lysis is a concern, the team may prescribe preventive treatment and a personalised fluid plan.

How to take dasatinib

Daily tablets

Take the prescribed dose once daily at a consistent time, with or without food. Swallow tablets whole with water; do not cut, crush or chew them. The commonly labelled adult dose is 100 mg daily in chronic-phase treatment, while some other specialist plans use 140 mg daily. Your own prescription may differ because of side effects, interactions or clinical circumstances.

Check the strength and number of tablets each time a supply arrives. Do not alternate strengths or combine old supplies to create a new dose without confirmation. Dose increases, reductions and treatment pauses belong to the treating team. In children, the dose is reassessed as weight changes; the US label specifies recalculation every three months or sooner when needed.

Oral suspension and swallowing problems

European Sprycel oral suspension is prepared from powder by a pharmacist or qualified healthcare professional. It has different dosing recommendations from tablets because the same milligram amount does not produce equivalent exposure. This applies to a change in either direction. Availability of a suspension in one country does not establish availability where you are treated.

Use the supplied oral syringe and the exact prescribed volume. For the reviewed European product, the instructions say to shake the closed bottle for 30 seconds before measuring each dose. Ask for a demonstration and repeat it back to the pharmacist. A kitchen teaspoon is not a measuring device. Do not prepare a homemade liquid by crushing tablets.

Missed doses, vomiting and pauses

If you miss a dose, skip it and take the next one at the usual time. Never double the dose. If you vomit just after taking dasatinib, do not take an extra dose; take the next scheduled dose unless the team advises a pause. Report repeated vomiting or difficulty keeping fluids down.

An accidental extra dose needs immediate medical advice; take the packaging and dose record with you if asked to attend hospital. Following a treatment hold, obtain a clear restart instruction. Feeling better or seeing a blood result online is not enough to decide that restarting is safe.

Monitoring during treatment

Blood counts help detect low infection-fighting neutrophils, low platelets and anaemia. The labelled schedule varies: in chronic-phase CML, US information specifies every two weeks for the first 12 weeks, then every three months or as needed. More advanced disease or acute-leukaemia plans usually need weekly counts for two months, then monthly or as clinically indicated.

Children receiving dasatinib with chemotherapy may need much more frequent testing. Counts are checked before each chemotherapy block, with checks every two days during consolidation until recovery. These examples explain why appointment schedules differ; follow the calendar issued by your own unit.

US information recommends liver testing before treatment and monthly afterwards, or as clinically indicated. Kidney function, electrolytes, weight and fluid balance may also need review. Report swelling, new cough, reduced exercise tolerance or breathlessness between appointments; a normal recent blood count cannot rule out fluid around the lungs or pulmonary hypertension.

Disease-response tests, including molecular testing when appropriate, serve a different purpose from safety blood tests. Ask which results guide response and when they will be discussed. Children also need growth and development checks. Hepatitis B carriers need monitoring during treatment and for several months after it ends.

Common side effects and practical care

Low blood counts and tiredness

Low neutrophils increase infection risk. Wash hands regularly and follow the unit's advice about infection exposure and food hygiene. Fever or feeling suddenly unwell needs prompt assessment, even if you were told the last count was satisfactory. Do not take fever medicine simply to postpone calling.

Anaemia can cause fatigue, dizziness and breathlessness. Pace activity and rest, but report a marked change rather than assuming all tiredness is expected. The team may check blood counts, other causes and whether a transfusion or treatment adjustment is needed.

Nausea, diarrhoea and mouth symptoms

Take prescribed anti-sickness medicines as directed. Small meals and frequent sips may help. Tell the team about repeated vomiting, watery stools, abdominal pain or reduced intake. Blood in stools, black stools, severe pain or fever require urgent contact because these are not symptoms to manage with diet alone.

Use a soft toothbrush and the recommended mouth care. Report ulcers, white patches or pain that affects eating and drinking. Ask for a dietitian if appetite or weight is falling. Fluid advice should account for heart or kidney problems and fluid retention; forcing a fixed large volume is not appropriate for everyone.

Skin, headache and body aches

Dryness or an itchy rash may improve with gentle washing, an unperfumed moisturiser and prescribed treatment. Macmillan advises sun protection, including at least SPF 30 and protective clothing. Report a spreading rash. Skin blistering, peeling or sores involving the mouth or eyes need urgent assessment before another dose. A severe reaction affecting skin and mucous membranes requires permanent discontinuation if no other cause is identified.

Headaches and muscle, joint or bone pain can occur. Ask which painkiller is safe because some increase bleeding risk or interact with treatment. A sudden severe headache, especially with weakness, confusion, vomiting or speech difficulty, requires emergency care rather than another painkiller.

Important side effects that need assessment

Fluid around the lungs and pulmonary hypertension

Dasatinib can cause fluid retention, including a pleural effusion, meaning fluid between the lung and chest wall. It can also affect fluid around the heart or in the lungs. New breathlessness, dry cough, chest discomfort, swollen ankles or rapid weight gain need prompt assessment. A chest X-ray or other tests may be required.

Treatment may involve a temporary hold, dose adjustment, medicines to remove fluid, a short steroid course or drainage when necessary. Do not start a diuretic or steroid yourself. Breathlessness has several possible causes, including infection, anaemia, heart problems and lung inflammation; symptoms alone cannot identify which is responsible.

Pulmonary arterial hypertension, or PAH, is increased pressure in the blood vessels supplying the lungs. It can develop after more than a year of treatment. Breathlessness, fatigue, faintness and fluid retention need investigation even after a long stable period. If PAH is confirmed, dasatinib must be permanently discontinued. Improvement after stopping is possible but is not guaranteed.

Bleeding and heart problems

Dasatinib can cause serious bleeding, including bleeding in the digestive tract or brain. Low platelets contribute, and platelet function may also be affected. Report unusual bruising, nosebleeds, bleeding gums, heavy periods or blood in urine promptly. Major bleeding, black stools with weakness, vomiting blood or neurological symptoms require emergency assessment.

Heart dysfunction and changes in rhythm can occur. Some people are at greater risk of QT prolongation, an electrical change that can lead to dangerous rhythms. Chest pain, fainting or a sustained racing or irregular heartbeat needs urgent care. Low potassium or magnesium and interacting medicines can add to this risk.

Liver, kidney and other serious problems

Liver injury may first appear on blood tests. Report yellow eyes or skin, dark urine, pale stools or persistent upper-abdominal discomfort. Hepatitis B reactivation is another reason for liver assessment and can be serious.

Tumour lysis syndrome occurs when rapid breakdown of cancer cells disturbs blood salts and kidney function. It is particularly relevant to some patients with a high disease burden. Reduced urine, severe vomiting, cramps, weakness, confusion or palpitations require urgent contact. Follow preventive medicines and fluid advice rather than self-treating with supplements.

Rare reports include serious kidney problems and thrombotic microangiopathy, involving injury and small clots in tiny blood vessels. New swelling, very little urine, unusual bruising or marked weakness needs assessment. If the team suspects thrombotic microangiopathy, treatment must be stopped while urgent investigations are performed. Certain confirming results mean it must not be restarted. These reports do not establish a predictable frequency for an individual.

Other medicines, supplements and vaccinations

Acid-reducing medicines: the product matters

With Sprycel, proton-pump inhibitors such as omeprazole and H2 blockers such as famotidine should not be coadministered because they can reduce absorption. Merely moving them a few hours apart is not the labelled solution. A simple antacid may be an alternative if taken at least two hours before or two hours after Sprycel.

Phyrago has different formulation evidence: its US label reports no clinically significant absorption change with omeprazole or famotidine. Its label advises avoiding antacids; if an antacid cannot be avoided, separate it by at least two hours before or after Phyrago. This difference is a reason for pharmacist checking, not permission to switch brands yourself. Other products require their own instructions.

Other important interactions

Strong CYP3A4 inhibitors or inducers can substantially change dasatinib levels. Examples include certain antifungals, antibiotics, antiviral medicines, tuberculosis medicines and seizure treatments. Avoid grapefruit and St John's wort. Have every new medicine checked, including a short course prescribed by another doctor. Strong inhibitors and inducers should generally be avoided; an unavoidable interaction needs specialist dose management.

Blood thinners, antiplatelet medicines and some painkillers can increase bleeding risk. Do not independently stop a prescribed blood thinner; the prescribers need to agree a safe plan. Medicines affecting heart rhythm also require review.

The September 2026 US Sprycel label adds a warning that dasatinib can delay clearance of high-dose methotrexate. If methotrexate is part of your hospital treatment, the team must account for this interaction and monitor its clearance and supportive treatment. Do not change either medicine yourself.

Discuss vaccines with the team. Non-live vaccines may be recommended; live vaccines can be unsuitable when immunity is weakened. The correct timing depends on blood counts and the whole treatment plan. Do not apply a generic waiting period from another medicine.

Everyday life, storage and practical support

Plan a daily reminder and arrange repeat prescriptions before supplies run out. Let the team know if cost, travel or side effects make regular dosing difficult. Avoid rationing tablets or taking planned breaks without agreement. Keep a current medicine list for dental care, hospital visits and travel.

Do not drive with dizziness, blurred vision or other symptoms that impair concentration. Report persistent changes rather than adjusting around them indefinitely. Tell the team before dental work or procedures so bleeding risk and treatment timing can be considered.

Store tablets in their original labelled packaging, away from children, heat and moisture. Follow the actual pack's temperature instructions. Wash hands after handling. Caregivers should wear disposable gloves if handling damaged tablets; avoid breathing in powder and ask the pharmacist how to manage it safely. Pregnant or breastfeeding caregivers should avoid exposure to the European suspension powder. Return unused treatment as instructed.

The prepared European Sprycel suspension must be refrigerated at 2–8°C (35.6–46.4°F), never frozen, and discarded 60 days after preparation. Check the pharmacy's discard date. This storage rule is for that prepared suspension, not every dasatinib product. Ask about transport and accidental temperature exposure.

Fertility, pregnancy and breastfeeding

Dasatinib can harm a developing baby. Discuss pregnancy intentions before treatment and contact the team immediately if pregnancy is suspected. US labels advise effective contraception during treatment and for 30 days afterwards for patients who can become pregnant and for male patients with partners who can become pregnant. European information specifies contraception during treatment without the same fixed post-treatment interval. Agree a clear plan for your supplied product and other medicines.

Do not breastfeed during treatment. US information extends this restriction for two weeks after the last dose; European information does not supply the same fixed restart interval. Ask the team when breast milk can safely be given. Expressing and discarding milk does not remove the restriction.

Future fertility is uncertain, and treatment should not be assumed to make someone infertile. Discuss sperm storage or other fertility-preservation options before starting when feasible. A wish to conceive is a reason for a planned specialist discussion, not an unsupervised interruption.

After treatment stops

Confirm why treatment is stopping, which symptoms still need review and what monitoring will continue. Follow the agreed contraception and breastfeeding intervals. Hepatitis B monitoring may continue for several months. New breathing symptoms, swelling or bleeding still deserve attention after the last dose.

A good molecular response does not by itself mean that stopping is safe. Any planned treatment-free period requires specialist selection and a monitoring plan. Never stop because you feel well or restart leftover tablets because a result worries you. Ask whom to contact between visits and what happens if another treatment is needed.

Frequently asked questions